Boston Scientific BSX announces its next round of earnings this Thursday, July 28, 2011. Get prepared with Benzinga's ultimate preview for Boston Scientific's second quarter earnings.
Earnings and Revenue:
Analysts are predicting an EPS reading of 8 cents per share and revenues of $1.94 billion. Wall Street will be looking to see how this quarter's numbers compare to the year-ago quarter's positive EPS of 6 cents per share on revenues of $1.93 billion. We'll have to wait for Thursday to see if Boston Scientific has accomplished the estimated 33.3% rise in EPS and 0.5% increase in revenues on a year-over-year basis.
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q1 | Q4 | Q3 | Q2 |
EPS Estimate | $0.04 | $0.10 | $0.06 | $0.03 |
EPS Actual | $0.14 | $0.20 | $0.12 | $0.06 |
Stock Performance:
At last check, shares of Boston Scientific were trading at $7.21. Shares are down 4.8% year to date. For a full 12 months, the return has risen by 17.6%. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.
- Long-term shareholders are already enjoying 12-month gains prior to the announcement
Average Stock Rating:
The average rating by analysts for Boston Scientific is a Hold. This rating has strengthened slightly over the past ninety days.
Competitors:
Want to check out the performance of Boston Scientific closest competitors? Take a look at some of the company's peers in the healthcare sector.
- Abbott Laboratories ABT: Hold with a $1.12 recent quarter EPS
- C.R. Bard BCR: Hold with a $1.57 recent quarter EPS
- Johnson & Johnson JNJ: Moderate Buy with a $1.28 recent quarter EPS
- Medtronic MDT: Hold with a $0.90 recent quarter EPS
Boston Scientific is in the medical products industry, which has experienced price/earnings growth of 1.5%.
Finally, a description of the company's main areas of operation: Boston Scientific offers medical devices used in interventional cardiology, cardiac rhythm management, peripheral interventions, endoscopy, gynecology, electrophysiology, neurovascular intervention and neuromodulation.
Take Action:
That's your advanced look at Boston Scientific's upcoming earnings numbers -- be ready to take quick action if the company's report contains any surprises. Also, check back in with us after the announcement for a full recap and what-to-do-next guide.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.